Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

24432 ARTÍCULOS , VIENDO DEL 2551 AL 2565

Circulating Biomarkers for Alzheimer's Disease: Unlocking the Diagnostic Potential in Low- and Middle-Income Countries, Focusing on Africa

Nwamekang Belinga L, Espourteille J, Wepnyu Njamnshi Y, Zafack Zeukang A, Rouaud O, Kongnyu Njamnshi A, Allali G, Richetin K.

Neurodegener Dis. 2024;24(1):26-40. doi: 10.1159/000538623. Epub 2024 Mar 29.

The associations between type 2 diabetes and plasma biomarkers of Alzheimer's disease in the Health and Aging Brain Study: Health Disparities (HABS-HD)

Yu F, Pituch KA, Maxfield M, Baena E, Geda YE, Pruzin JJ, Coon DW, Shaibi GQ; HABS-HD Study Team.

PLoS One. 2024 Apr 1;19(4):e0295749. doi: 10.1371/journal.pone.0295749. eCollection 2024.

Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer's disease

Gonzalez-Ortiz F, Kirsebom BE, Contador J, Tanley JE, Selnes P, Gísladóttir B, Pålhaugen L, Suhr Hemminghyth M, Jarholm J, Skogseth R, Bråthen G, Grøndtvedt G, Bjørnerud A, Tecelao S, Waterloo K, Aarsland D, Fernández-Lebrero A, García-Escobar G, Navalpotro-Gómez I, Turton M, Hesthamar A, Kac PR, Nilsson J, Luchsinger J, Hayden KM, Harrison P, Puig-Pijoan A, Zetterberg H, Hughes TM, Suárez-Calvet M, Karikari TK, Fladby T, Blennow K.

Nat Commun. 2024 Apr 4;15(1):2908. doi: 10.1038/s41467-024-47286-5.

A critical appraisal of blood-based biomarkers for Alzheimer's disease

Lista S, Mapstone M, Caraci F, Emanuele E, López-Ortiz S, Martín-Hernández J, Triaca V, Imbimbo C, Gabelle A, Mielke MM, Nisticò R, Santos-Lozano A, Imbimbo BP.

Ageing Res Rev. 2024 Apr;96:102290. doi: 10.1016/j.arr.2024.102290. Epub 2024 Apr 4.

Increased molar ratio of free fatty acids to albumin in blood as cause and early biomarker for the development of cataracts and Alzheimer's disease

Glaesser D, Iwig M.

Exp Eye Res. 2024 Jun;243:109888. doi: 10.1016/j.exer.2024.109888. Epub 2024 Apr 6.

Prominent Perspective on Existing Biological Hallmarks of Alzheimer's Disease

Singh N, Sharma S, Ghosh KK, Gupta B, Kuca K.

Curr Top Med Chem. 2024;24(13):1120-1133. doi: 10.2174/0115680266292514240404040341.

Cell-Free DNA As Peripheral Biomarker of Alzheimer's Disease

Khemka S, Sehar U, Manna PR, Kshirsagar S, Reddy PH.

Aging Dis. 2024 Mar 29;16(2):787-803. doi: 10.14336/AD.2024.0329.

Kallikrein-related peptidase's significance in Alzheimer's disease pathogenesis: A comprehensive survey

Boumali R, Urli L, Naim M, Soualmia F, Kinugawa K, Petropoulos I, El Amri C.

Biochimie. 2024 Nov;226:77-90. doi: 10.1016/j.biochi.2024.04.001. Epub 2024 Apr 10.

Feasibility of Using Magnetic Resonance Spectroscopy Test Biomarkers to Diagnose Alzheimer's Disease: Systematic Evaluation and Meta-Analysis

Wei B, Xu Y, Du Y, Zhou J, Zhong F, Wu C, Lou Y.

Actas Esp Psiquiatr. 2024 Apr;52(2):161-171. doi: 10.62641/aep.v52i2.1552.

Unveiling New Strategies Facilitating the Implementation of Artificial Intelligence in Neuroimaging for the Early Detection of Alzheimer's Disease

Etekochay MO, Amaravadhi AR, González GV, Atanasov AG, Matin M, Mofatteh M, Steinbusch HW, Tesfaye T, Praticò D.

J Alzheimers Dis. 2024;99(1):1-20. doi: 10.3233/JAD-231135.

[On the road to biological blood diagnosis of Alzheimer's disease?]

Delaby C, Lehmann S.

Med Sci (Paris). 2024 Apr;40(4):351-360. doi: 10.1051/medsci/2024037. Epub 2024 Apr 23.

Clinical value of plasma ALZpath pTau217 immunoassay for assessing mild cognitive impairment

Lehmann S, Schraen-Maschke S, Vidal JS, Delaby C, Buee L, Blanc F, Paquet C, Allinquant B, Bombois S, Gabelle A, Hanon O; BALTAZAR study group.

J Neurol Neurosurg Psychiatry. 2024 Oct 16;95(11):1046-1053. doi: 10.1136/jnnp-2024-333467.

Short-Term Practice Effects on Cognitive Tests Across the Late Life Cognitive Spectrum and How They Compare to Biomarkers of Alzheimer's Disease

Duff K, Hammers DB, Koppelmans V, King JB, Hoffman JM.

J Alzheimers Dis. 2024;99(1):321-332. doi: 10.3233/JAD-231392.

Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer's disease: a systematic review

Oosthoek M, Vermunt L, de Wilde A, Bongers B, Antwi-Berko D, Scheltens P, van Bokhoven P, Vijverberg EGB, Teunissen CE.

Alzheimers Res Ther. 2024 Apr 27;16(1):93. doi: 10.1186/s13195-024-01456-1.

Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial

Wagemann O, Liu H, Wang G, Shi X, Bittner T, Scelsi MA, Farlow MR, Clifford DB, Supnet-Bell C, Santacruz AM, Aschenbrenner AJ, Hassenstab JJ, Benzinger TLS, Gordon BA, Coalier KA, Cruchaga C, Ibanez L, Perrin RJ, Xiong C, Li Y, Morris JC, Lah JJ, Berman SB, Roberson ED, van Dyck CH, Galasko D, Gauthier S, Hsiung GR, Brooks WS, Pariente J, Mummery CJ, Day GS, Ringman JM, Mendez PC, St George-Hyslop P, Fox NC, Suzuki K, Okhravi HR, Chhatwal J, Levin J, Jucker M, Sims JR, Holdridge KC, Proctor NK, Yaari R, Andersen SW, Mancini M, Llibre-Guerra J, Bateman RJ, McDade E; Dominantly Inherited Alzheimer Network–Trials Unit.

JAMA Neurol. 2024 Jun 1;81(6):582-593. doi: 10.1001/jamaneurol.2024.0991.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias